Bull
$201.68
Scenario price
$384.020
+0.998 (+0.26%)At close
West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.
West Pharmaceutical Services Inc is a good buy right now, trading at $384.02 with a strong recent performance of +4.92% over the last 5 days and a year-to-date change of +38.94%. The company has shown robust growth, with Q2 2026 sales increasing to $872 million, a 13.8% rise, and an adjusted EPS of $2.37, exceeding expectations by $0.29. However, the RSI is at 75.786, indicating it may be overbought, which is a risk to consider.
Barclays
$440
2026-10-07
Barclays
2026-10-07
Price Target
$440
Morgan Stanley
$400
2026-09-22
Morgan Stanley
2026-09-22
Price Target
$400
UBS
$415
2026-09-09
UBS
2026-09-09
Price Target
$415
Citi
$412
2026-08-03
Citi
2026-08-03
Price Target
$412
Evercore ISI
$425
2026-07-27
Evercore ISI
2026-07-27
Price Target
$425
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

West Pharmaceutical Services to Release Q3 Financial Results

West Pharmaceutical Showcases Innovative Injection Solutions at CPHI Worldwide in Milan

West Pharmaceutical Services Stock Recovery

Latest Wall Street Ratings and Price Target Analysis

Ecolab Reports Strong Q2 Performance Amid Cost Concerns
West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
West Pharmaceutical Services Inc is a good buy right now, trading at $384.02 with a strong recent performance of +4.92% over the last 5 days and a year-to-date change of +38.94%. The company has shown robust growth, with Q2 2026 sales increasing to $872 million, a 13.8% rise, and an adjusted EPS of $2.37, exceeding expectations by $0.29. However, the RSI is at 75.786, indicating it may be overbought, which is a risk to consider.
7 analysts cover WST: 4 rate it Buy, 2 Hold and 1 Sell. The average price target is 348.70.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.